天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Current opinion in pediatrics >>article
Current opinion in pediatrics

Current opinion in pediatrics

IF: 2.2
Download PDF

Bivalirudin in pediatric extracorporeal membrane oxygenation

Published:1 June 2022 DOI: 10.1097/MOP.0000000000001131
L. Ryerson,?A. McMichael

Abstract

Purpose of review This review summarizes the current literature surrounding the use of bivalirudin as an alternative anticoagulant for pediatric extracorporeal membrane oxygenation (ECMO) patients. Recent findings Recent single center studies describe that bivalirudin may be associated with decreased blood product transfusion, decreased cost and similar clinical outcomes for pediatric ECMO patients who have failed unfractionated heparin (UFH) anticoagulation. aPTT is the most common test to monitor bivalirudin but has several limitations. Other tests including dilute thrombin time (dTT) and viscoelastic assays are promising but more study is needed. Current evidence suggests that bivalirudin is a well tolerated and effective alternative anticoagulant for pediatric ECMO patients who have failed UFH anticoagulation but prospective studies are needed to confirm these results. Summary Bivalirudin is a promising alternative anticoagulant for pediatric ECMO patients who have failed UFH. Large prospective, multicenter studies are needed to confirm safety and efficacy.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Bivalirudin 128270-60-0 C98H138N24O33 428 suppliers $55.00-$2425.50
ACCUCLOT UNFRACTIONATED HEPARIN*(UFH) CALIBRATOR SET - Inquiry

Similar articles

IF:4

Evaluation of Bivalirudin As an Alternative to Heparin for Systemic Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation.

Pediatric Critical Care Medicine Mohammed Hamzah, Angela M Jarden,etc Published: 1 September 2020
IF:3.4

Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients.

Pediatric Drugs Hannu Kokki,etc Published: 1 October 2010
IF:3.4

Sodium Thiosulfate: Pediatric First Approval.

Pediatric Drugs Sohita Dhillon,etc Published: 1 March 2023